Last Update 21 Feb 26

AVAH: Refined Discount Rate Assumptions Will Support Future Earnings Reassessment

Aveanna Healthcare Holdings' analyst price target has been nudged higher to $11, with analysts pointing to modest tweaks in the discount rate and P/E assumptions, supported by new target increases from Barclays, RBC Capital, and UBS.

Analyst Commentary

Recent research updates cluster around a higher price target near $11, with analysts fine tuning their discount rate and P/E assumptions rather than making wholesale changes to their views on Aveanna Healthcare Holdings.

Bullish Takeaways

Bullish analysts are framing the higher target as a valuation clean up, arguing that their prior discount rates and P/E multiples were too conservative relative to how they now view the company’s risk profile.
The step ups of $2, $1 and $0.50 in the various target updates suggest a view that Aveanna’s execution track record and outlook justify a slightly richer multiple on forward earnings than previously used.
Supportive analysts see the cluster of target changes as a sign that the stock’s risk and reward are better aligned in their models, with the updated discount rate assumptions pointing to a more balanced view of longer term cash flows.
Across the new work, the message for shareholders is that Aveanna’s current share price is now being assessed against a more refined valuation framework rather than a materially different operating story.

Bearish Takeaways

Even with the higher targets, bearish analysts emphasize that the changes are modest, which signals that there are still questions around execution and the consistency of future results.
Cautious voices highlight that any uplift tied to P/E tweaks can reverse if earnings or cash conversion fall short of expectations, so they remain restrained in how far they push valuation multiples.
Some analysts flag that the reliance on discount rate adjustments to support the new target range leaves limited room for error if funding conditions, reimbursement trends or cost pressures move against the company.
Overall, the tone of the cautious commentary is that the updated targets refine the numbers rather than fully address underlying operational and financial risks that could cap longer term upside.

What's in the News

Aveanna Healthcare Holdings issued updated earnings guidance for the year ending January 3, 2026, with expected revenue of approximately $2.425b to $2.445b and net income of approximately $181m to $220m (Corporate guidance).
The company also provided earnings guidance for the year ending January 2, 2027, with expected revenue between $2.54b and $2.56b (Corporate guidance).
For 2025, Aveanna Healthcare Holdings updated its revenue guidance to a range of $2.425b to $2.445b, compared with previous guidance of greater than $2.375b (Corporate guidance).

Valuation Changes

Fair Value: Held steady at $11.0, with no change in the headline target figure.
Discount Rate: Adjusted slightly from 7.34% to 7.38%, a move of roughly 0.04 percentage points, indicating a marginal shift in the risk assumption used in the model.
Revenue Growth: Kept effectively unchanged at about 6.73%, suggesting no revision to the top line growth outlook in the latest update.
Net Profit Margin: Left effectively unchanged at about 5.39%, with only a very small numerical refinement to the underlying input.
Future P/E: Tweaked slightly from 23.11x to 23.14x, a very modest move that fine tunes rather than reworks the earnings multiple assumption.

1 view

Key Takeaways

Strong demand for in-home healthcare and a growing aging population are expanding Aveanna's market opportunity and supporting sustained long-term growth.
Strategic payer relationships, efficiency initiatives, and recent acquisitions are boosting margins, cash flow, and future earnings potential.
Reliance on government funding, financial leverage, workforce challenges, and shifting healthcare delivery models threaten Aveanna's growth, margins, and long-term business sustainability.

Catalysts

About Aveanna Healthcare Holdings

A diversified home care platform company, provides pediatric and adult healthcare services in the United States.What are the underlying business or industry changes driving this perspective?

Accelerating adoption of home-based healthcare and increasing patient preference for in-home care are driving strong and sustained demand for Aveanna's services, which management repeatedly noted remains robust and outstrips the company's current capacity, supporting the potential for significant future revenue growth as the company hires and retains more caregivers.
The demographic shift toward an aging U.S. population and the rising prevalence of chronic conditions are expected to increase long-term demand for home and community-based care and skilled nursing, expanding Aveanna's total addressable market and underpinning multi-year top-line and EBITDA growth.
Successful execution of the preferred payer strategy-including a rapid increase in preferred payer agreements in all segments and legislative progress on rate enhancements-supports higher reimbursement rates, better operating leverage, and improved net margins into 2025 and beyond.
Ongoing investment in operational efficiencies (such as modernizing digital workflows, centralized billing, and preferred payer alignment) is expected to drive further margin expansion and increase free cash flow, strengthening liquidity and enabling future M&A-led growth.
Recent M&A activity, notably the Thrive Skilled Pediatric acquisition, expands Aveanna's geographic footprint, service offerings, and payer relationships, supporting both near-term adjusted EBITDA accretion and positioning the company for significant earnings growth as integration is completed and additional tuck-in acquisitions are pursued.

Aveanna Healthcare Holdings Earnings and Revenue Growth

Aveanna Healthcare Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Aveanna Healthcare Holdings's revenue will grow by 7.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.9% today to 5.8% in 3 years time.
Analysts expect earnings to reach $156.7 million (and earnings per share of $0.52) by about September 2028, up from $18.6 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 15.1x on those 2028 earnings, down from 93.9x today. This future PE is lower than the current PE for the US Healthcare industry at 20.9x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.1%, as per the Simply Wall St company report.

Aveanna Healthcare Holdings Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent wage inflation and ongoing challenges in caregiver recruitment/retention, even with targeted wage pass-throughs, could compress long-term net margins and impede revenue growth if Aveanna fails to meet increasing service demand.
Heavy dependence on Medicaid and Medicare reimbursement exposes Aveanna to significant regulatory/budgetary risks-state and federal pressures on Medicaid budgets and the proposed Medicare home health cuts (6.4% in 2026) could limit rate increases or even result in rate reductions, reducing revenue and profitability.
High leverage, with $1.47 billion in variable-rate debt, constrains financial flexibility and increases sensitivity to interest rate environments and industry downturns, posing long-term risks to earnings and raising the threat of deleveraging challenges.
Timing-related revenue and EBITDA benefits (e.g., value-based payment uplifts, one-time legal settlements) have temporarily boosted results, but normalization of these factors may reveal less robust underlying earnings growth, potentially disappointing future earnings expectations.
The ongoing shift toward technology-enabled home healthcare (telehealth, remote monitoring) among payers and patients could reduce the demand for Aveanna's traditional in-person services, challenging its core business model and impacting long-term top-line growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $7.556 for Aveanna Healthcare Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $6.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $2.7 billion, earnings will come to $156.7 million, and it would be trading on a PE ratio of 15.1x, assuming you use a discount rate of 7.1%.
Given the current share price of $8.34, the analyst price target of $7.56 is 10.4% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Aveanna Healthcare Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Improved Earnings Visibility and Liquidity Changes Will Shape Capacity Expansion